Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The revision label on the page was updated from v3.6.6 to v3.7.0. This indicates an updated edition of the study documents.
    Difference
    0.0%
    Check dated 2026-09-15T20:47:08.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.5 to v3.6.6, signaling a new build of the page. It likely reflects minor fixes or updates to the page rather than changes to the study data.
    Difference
    0.0%
    Check dated 2026-09-01T18:20:04.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    A new line '2018 ( U.S. NIH Grant/Contract )' was added to the study's identifiers section. This records NIH funding information associated with the trial.
    Difference
    0.0%
    Check dated 2026-08-25T19:49:22.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The page now shows an updated revision label Revision: v3.6.5, and the Plain Language Summary section has been removed along with the older Revision: v3.6.4.
    Difference
    0.0%
    Check dated 2026-08-11T18:55:12.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.3 to v3.6.4, reflecting a minor update to the page's version metadata rather than its content.
    Difference
    0.0%
    Check dated 2026-07-21T12:52:26.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    - Revision: v3.6.3 is now shown, replacing v3.6.0, signaling a version update to the page's underlying system. This change updates metadata and does not alter the study details or core content.
    Difference
    0.0%
    Check dated 2026-06-30T02:36:14.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.